Egypt Cancer Immunotherapy Market Analysis

Egypt Cancer Immunotherapy Market Analysis


$ 3999

Egypt's cancer immunotherapy market is expected to witness growth from $315 Mn in 2022 to $610 Mn in 2030 with a CAGR of 8.6% for the forecasted year 2022-30. The rising prevalence of cancer and the improvements in healthcare spending in Egypt are responsible for the growth of the market. The Egypt cancer immunotherapy market is segmented by type, application, and end user. Pharco B, Amoun Pharmaceutical, and AstraZeneca are the major players in the Egypt cancer immunotherapy market.

ID: IN10EGPH032 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Dr. Parul Choudhary

Buy Now

Egypt Cancer Immunotherapy Market Executive Analysis

Egypt's cancer immunotherapy market is expected to witness growth from $315 Mn in 2022 to $610 Mn in 2030 with a CAGR of 8.6% for the forecasted year 2022-30. According to the finance minister, the 2018 budget allotment for Egypt's health sector has increased by 14% to EGP 111.2 Bn. This is an increase of EGP 13.3 Bn over the budget from the prior year. Additionally, he mentioned that the current fiscal year's health investments had increased by 30% as compared to the prior year. The minister also emphasized the higher risk allowance for medical employees, including doctors and nurses.  Additionally, he mentioned that the emergency incentive, lodging, and night shift allowances had all been raised.

According to the National Plan for Cancer Control 2019–2022, which was created by the National Cancer Committee at the Ministry of Health, cancer rates are predicted to rise by three times their present level by 2050. According to the National Cancer Control Plan, the incidence of cancer is currently 113 per 100,000 people and is projected to rise to 341 per 100,000 people by 2050. Males are more likely to develop liver cancer than females are to develop lung cancer (5.69 % vs. 33.63 %). Females are more likely to develop breast cancer (32.04%), liver cancer (13.54%), and ovarian cancer (4.12%) than males.

The alternative medicinal approach to combat cancer is immunotherapy. Immunotherapy, in its broadest sense, refers to therapeutic actions that stimulate or inhibit immune responses in the fight against cancer. It may either seek to boost overall immune responses or directly engage the immune system to combat cancer cells. The three main immunotherapies that are utilized to treat numerous tumours are immune checkpoint inhibitors, CAR-T cell therapy, and monoclonal antibodies. There are numerous clinical trials planned to look at the efficacy of cancer immunotherapies in Egypt. Cancer immune reprogramming can be divided into three phases: (a) activating the innate and adaptive immune systems to destroy cancer cells (eradication phase); (b) maintaining the viability of abnormal malignant cells that can activate immune reprogramming (equipoise phase); and (c) creating an immunosuppressive microenvironment and low-immunogenic tumours (escape phase).

Small messengers called cytokines let immune system cells communicate with one another and respond to a specific antigen in a coordinated manner. At the tumour location, cytokines can directly stimulate stromal cells and effector cells, enhancing CD8+ T cells' ability to recognize tumour cells. For the treatment of cancer, the FDA has approved the use of two cytokines: IFN- 2b has been used as an adjuvant in the treatment of Stage III melanoma, and large dosages of IL-2 are given for metastatic melanoma and renal cell carcinoma.

The use of a patient's own cells to treat cancer is a developing area of immune treatment. the adoption cell transfer (ACT) process. There are various ACTs, but (CAR) T-cell therapy is the most common. In (CAR) T-cell therapy, autologous T cells from the patients are isolated and modified in vitro by genetic engineering. The extracellular domain (ScFv) of the T cell receptor can bind to and recognize tumour antigens, hinge or spacer sections, transmembrane domains, and intracellular domains, which are made up of the signalling domain and the co-stimulatory CD28 domain, and its recognition is MHC independent. Chimeric antigen receptor (CAR) is the name of the novel T cell receptor, and (CAR) T cells are T cells that express this receptor. Patients are given (CAR) T-cells that have been produced in enormous quantities in the lab. The treatment of advanced blood malignancies has used this therapy. This treatment is very targeted, has fewer adverse effects, and has the benefit of not having any drug resistance.

Egypt Cancer Immunotherapy Market Analysis

Market Dynamics

Market Growth Drivers

With an estimated 115,000 new instances of cancer identified each year, Egypt has one of the highest rates of cancer in the entire globe. The desire for innovative and potent therapies, such as immunotherapy, is being driven by the increased incidence of cancer. The Egyptian government is putting more emphasis on cancer treatment and investing in facilities and technology. This backing is anticipated to accelerate the nation's adoption of cancer immunotherapy. The government of Egypt is investing in the construction of its healthcare infrastructure, which is resulting in an increase in healthcare costs. Because of this, more patients have access to cancer therapies like immunotherapy. The Egyptian government has taken measures to speed up the approval procedure for novel cancer therapies, such as immunotherapy. This has facilitated the commercialization of novel therapies and will likely fuel the expansion of the Egypt cancer immunotherapy market.

Market Restraints

Many patients in Egypt still lack access to even the most basic healthcare services, let alone specialized cancer care, despite government efforts to increase healthcare access. This might restrict how widely cancer immunotherapy is used throughout the nation. Numerous patients in Egypt might not be able to afford immunotherapy therapies since they can be pricey. The market size for these treatments might be constrained by this, particularly in the absence of extensive insurance coverage. Accurate cancer detection is a need for effective cancer therapy, which in turn necessitates the availability of cutting-edge diagnostic tools like PET/CT scans. However, the lack of accessibility to such technology in Egypt may restrict the use of immunotherapy therapies. Cancer immunotherapy research and development are underdeveloped in Egypt, which may restrict the Egypt cancer immunotherapy market's access to the latest treatments.

Competitive Landscape

Key Players

  • Liptis (EGY)
  • Ateco Pharma (EGY)
  • Copad pharma (EGY)
  • Pharco B (EGY)
  • Amoun Pharmaceutical (EGY)
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • ELI Lilly
  • F Hoffman-La Roche
  • Janssen
  • Merck

Healthcare Policies and Regulatory Landscape

The universal healthcare system in Egypt, which offers all individuals access to fundamental healthcare services, covers cancer treatment. However, patients may need to travel to larger cities for treatment because access to specialized cancer care can be limited in some places. The National Cancer Institute (NCI) was founded by the Egyptian government to regulate cancer care and treatment in the nation and to establish payment standards for cancer therapy. The NCI establishes policies for reimbursement for these treatments as well as funds cancer therapies, such as immunotherapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Cancer Immunotherapy Segmentation

By Type (Revenue, USD Billion):

  • Monoclonal Antibodies
  • Cancer Vaccines
  • Checkpoint Inhibitors
  • Immunomodulators
  • PD-1/PD-L1
  • CTLA-4

By Application (Revenue, USD Billion):

  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

By End User (Revenue, USD Billion):

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Cancer Research Centers

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Pharco B, Amoun Pharmaceutical and AstraZeneca are the major players in the Egypt cancer immunotherapy market.

The Egypt cancer immunotherapy market is expected to grow from $315 Mn in 2022 to $610 Mn in 2030 with a CAGR of 8.6% for the forecasted year 2022-2030.

The Egypt cancer immunotherapy market is segmented by type, application, and end user.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 06 December 2023
Updated by: Ritu Baliya

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up